| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| NTLA | 38.53% | $1.11B | -53.25% | 0.00% |
| VICR | 38.53% | $2.07B | +37.48% | 0.00% |
| OLED | 37.32% | $7.67B | -25.94% | 1.05% |
| WNC | 36.69% | $480.67M | -47.44% | 2.77% |
| SLAB | 36.60% | $4.97B | +37.05% | 0.00% |
| CTS | 36.33% | $1.33B | -10.75% | 0.36% |
| KLIC | 36.23% | $1.94B | -25.30% | 2.20% |
| SON | 36.07% | $4.60B | -5.89% | 4.47% |
| HCAT | 35.82% | $282.58M | -34.30% | 0.00% |
| COHU | 35.82% | $953.77M | -38.54% | 0.00% |
| AVT | 35.81% | $4.71B | +9.84% | 2.34% |
| GPRO | 35.55% | $116.59M | -47.14% | 0.00% |
| RXRX | 35.38% | $2.12B | -29.12% | 0.00% |
| VECO | 35.11% | $1.27B | -55.33% | 0.00% |
| CSGP | 34.81% | $34.35B | +10.28% | 0.00% |
| BLFS | 34.54% | $1.08B | +13.58% | 0.00% |
| ARCT | 34.48% | $369.38M | -37.89% | 0.00% |
| BHE | 34.44% | $1.44B | +0.58% | 1.68% |
| PX | 34.35% | $1.20B | +28.67% | 1.33% |
| BEAM | 34.34% | $2.00B | -15.33% | 0.00% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CME | -17.32% | $99.39B | +40.68% | 3.86% |
| CBOE | -17.12% | $24.23B | +35.36% | 1.09% |
| EZPW | -12.47% | $763.04M | +35.32% | 0.00% |
| RYAN | -12.17% | $8.33B | +14.50% | 0.70% |
| PPC | -11.98% | $10.84B | +33.46% | 0.00% |
| COR | -11.04% | $56.44B | +30.86% | 0.74% |
| KR | -10.81% | $46.43B | +38.38% | 1.85% |
| CHD | -10.65% | $24.14B | -7.11% | 1.19% |
| LITB | -9.81% | $21.24M | -78.57% | 0.00% |
| ED | -9.48% | $36.00B | +12.64% | 3.34% |
| RCKY | -9.45% | $176.46M | -30.69% | 2.60% |
| EXC | -9.10% | $43.33B | +23.58% | 3.62% |
| MCK | -8.88% | $88.11B | +20.93% | 0.40% |
| MO | -8.82% | $99.67B | +28.77% | 6.90% |
| VTR | -8.65% | $28.41B | +21.44% | 2.95% |
| PSQH | -8.63% | $98.82M | -36.55% | 0.00% |
| CCEC | -8.51% | $1.02B | +3.91% | 2.58% |
| CIG.C | -8.40% | $2.65B | +29.61% | 0.00% |
| PGR | -7.87% | $151.13B | +22.60% | 1.89% |
| AJG | -7.31% | $80.86B | +20.22% | 0.79% |
Current Value
$0.701 Year Return
Current Value
$0.701 Year Return
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| ACGL | <0.01% | $33.12B | -4.82% | 0.00% |
| CNK | -0.01% | $3.47B | +41.29% | 0.53% |
| STG | 0.04% | $30.78M | -22.51% | 0.00% |
| BJ | -0.09% | $14.41B | +26.76% | 0.00% |
| VZ | -0.13% | $183.79B | +6.01% | 6.18% |
| CCEP | 0.13% | $43.12B | +27.16% | 2.32% |
| ASPS | -0.15% | $108.30M | -4.13% | 0.00% |
| NEUE | -0.18% | $61.24M | +29.92% | 0.00% |
| CPB | -0.23% | $9.52B | -29.04% | 4.82% |
| ALHC | 0.28% | $2.69B | +71.20% | 0.00% |
| TU | 0.29% | $24.75B | +7.77% | 7.12% |
| FDP | 0.34% | $1.59B | +52.62% | 3.31% |
| CLX | -0.37% | $15.36B | -5.89% | 3.90% |
| AWK | -0.41% | $27.36B | +9.65% | 2.21% |
| PRA | -0.43% | $1.17B | +89.68% | 0.00% |
| NGD | -0.49% | $3.88B | +132.23% | 0.00% |
| AON | 0.50% | $75.91B | +19.26% | 0.78% |
| COCO | 0.50% | $2.11B | +33.54% | 0.00% |
| HMY | -0.51% | $8.87B | +52.35% | 1.21% |
| AMT | -0.54% | $104.32B | +14.40% | 3.00% |
Yahoo
Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today reported new long-term open-label extension (OLE) data from its phase 2 EMPhASIS trial of lead asset, orally available nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), in patients with relapsing-remitting multiple sclerosis (RRMS).
Finnhub
Immunic, Inc. reported new long-term open-label extension data from its phase 2 EMPhASIS trial of lead asset, orally available nuclear receptor-related 1 activator, vidofludimus calcium , in...
SeekingAlpha
IMUX stock's drop appears to be an overreaction, given positive disability progression data and clean safety profile. Click to read why IMUX is a Strong Buy.
Yahoo
Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, announced the completion of enrollment for both phase 3 ENSURE trials of lead asset, nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), in patients with relapsing multiple sclerosis and additional phase 2 CALLIPER trial data in patients with progressive multiple sclerosis underlining the
Finnhub
Immunic Therapeutics Developing Selective Oral Therapies in Immunology NASDAQ: IMUX | June 2025 ...
Finnhub
Immunic, Inc. announced the completion of enrollment for both phase 3 ENSURE trials of lead asset, nuclear receptor-related 1 activator, vidofludimus calcium , in patients with relapsing multiple...
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| FXC | 0.09% | $93.16M | 0.4% |
| GSST | 0.13% | $921.46M | 0.16% |
| IBTP | -0.14% | $143.92M | 0.07% |
| CCOR | -0.17% | $51.66M | 1.18% |
| SHAG | 0.31% | $43.05M | 0.12% |
| FLGV | 0.33% | $1.03B | 0.09% |
| GVI | 0.38% | $3.42B | 0.2% |
| BSMR | -0.49% | $255.87M | 0.18% |
| CGSM | 0.53% | $709.45M | 0.25% |
| DFNM | -0.61% | $1.57B | 0.17% |
| BWX | -0.68% | $1.53B | 0.35% |
| IGOV | 0.68% | $1.22B | 0.35% |
| JMST | 0.73% | $4.06B | 0.18% |
| JPST | -0.74% | $31.90B | 0.18% |
| UTEN | 0.79% | $210.24M | 0.15% |
| BSMW | -0.83% | $107.45M | 0.18% |
| BNDX | 0.83% | $67.52B | 0.07% |
| FLIA | 0.96% | $687.42M | 0.25% |
| CLIP | 0.97% | $1.51B | 0.07% |
| IEF | -0.97% | $34.88B | 0.15% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BTAL | -30.00% | $296.22M | 1.43% |
| VIXY | -27.92% | $164.54M | 0.85% |
| TAIL | -25.71% | $99.63M | 0.59% |
| IVOL | -17.64% | $347.03M | 1.02% |
| XONE | -15.05% | $625.28M | 0.03% |
| BILS | -14.57% | $3.81B | 0.1356% |
| UTWO | -14.26% | $379.52M | 0.15% |
| XHLF | -14.25% | $1.73B | 0.03% |
| WEAT | -13.07% | $117.15M | 0.28% |
| SPTS | -12.02% | $5.80B | 0.03% |
| STPZ | -11.38% | $450.47M | 0.2% |
| FTSM | -11.17% | $6.37B | 0.45% |
| IBTG | -10.96% | $1.92B | 0.07% |
| LDUR | -10.84% | $929.65M | 0.5% |
| IBTH | -9.98% | $1.62B | 0.07% |
| VGSH | -9.63% | $22.80B | 0.03% |
| SHY | -9.02% | $23.83B | 0.15% |
| YEAR | -7.84% | $1.47B | 0.25% |
| CORN | -7.78% | $44.67M | 0.2% |
| SCHO | -7.48% | $11.03B | 0.03% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| ARKG | 41.75% | $1.02B | 0.75% |
| GNOM | 39.28% | $44.57M | 0.5% |
| QCLN | 39.13% | $400.76M | 0.56% |
| XBI | 38.91% | $4.82B | 0.35% |
| IWC | 38.61% | $818.14M | 0.6% |
| PBW | 37.78% | $271.53M | 0.65% |
| ICVT | 37.32% | $2.53B | 0.2% |
| ACES | 37.32% | $92.99M | 0.55% |
| KOMP | 36.77% | $2.29B | 0.2% |
| IWO | 36.70% | $11.60B | 0.24% |
| CWB | 35.92% | $3.88B | 0.4% |
| IWM | 35.75% | $63.72B | 0.19% |
| GSSC | 35.70% | $561.54M | 0.2% |
| VTWO | 35.66% | $12.52B | 0.07% |
| IWMY | 35.32% | $119.32M | 1.02% |
| BUZZ | 35.10% | $65.84M | 0.76% |
| PBD | 34.98% | $72.92M | 0.75% |
| SCHA | 34.80% | $17.26B | 0.04% |
| KJAN | 34.69% | $287.30M | 0.79% |
| METV | 34.61% | $300.09M | 0.59% |
